Motif Bio PLC Presentation at BIO International Convention
June 14 2017 - 2:01AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
14 June 2017
Motif Bio plc
("Motif Bio" or the "Company")
Presentation at BIO International Convention
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that the Company will present at BIO 2017 being held at the San
Diego Convention Center, 111 West Harbor Drive, San Diego from
19-22 June 2017.
The presentation will provide information on the progress of its
novel antibiotic candidate, iclaprim, and will take place at 3.30pm
on Wednesday, 21 June in Presentation Theater 3. The presentation
will be available shortly after on the company website:
www.motifbio.com
The BIO International Convention brings together over 16,000
biotechnology and pharma leaders, covering a wide spectrum of life
sciences areas including drug discovery, biomanufacturing,
genomics, biofuels, nanotechnology and cell therapy - for more
information see: http://convention.bio.org
For further details please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Rob Dickey (Chief Financial
Officer)
Peel Hunt LLP (NOMAD
& BROKER) + 44 (0)20 7418 8900
Dr. Christopher Golden
Oliver Jackson
Northland Capital Partners
Limited (BROKER) +44 (0)20 3861 6625
Patrick Claridge/ David
Hignell
John Howes/ Rob Rees
(Broking)
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or
PR & IR) motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN
IR) +49 (0)89 210 2280
Raimund Gabriel
About Motif Bio: www.motifbio.com
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP),
infections often caused by MRSA (methicillin resistant
Staphylococcus aureus). Having completed the REVIVE-1 trial,
patients are currently being enrolled and dosed in a second global
Phase 3 clinical trial (REVIVE-2) with an intravenous formulation
of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2
is expected in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGMVKFZGNZM
(END) Dow Jones Newswires
June 14, 2017 02:00 ET (06:00 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024